Durable remission without ongoing treatment in a disease with median survival under one year
In the long struggle against prostate cancer's most unforgiving forms, a trial presented in Chicago this June offered something rare: a reason for measured hope. The CHAMP trial combined chemotherapy with dual immunotherapy for men whose neuroendocrine and aggressive-variant prostate cancers had historically offered median survival of less than a year, and found that 74 percent remained free of radiographic progression at six months — a statistically significant leap beyond what platinum chemotherapy alone has historically achieved. It is not yet proof of cure, nor even of extended survival, but it is a signal that the immune system, properly enlisted, may find purchase even in cancers that have learned to evade nearly everything else.
- Neuroendocrine and aggressive-variant prostate cancers kill fast — often within a year — and standard chemotherapy has offered only modest, short-lived control for a heavily pretreated population with few remaining options.
- The CHAMP trial pushed into this difficult terrain by layering two immune checkpoint inhibitors onto an already intensive platinum-based chemotherapy doublet, testing whether the immune system could be awakened in tumors that had evolved to ignore conventional treatment.
- Seventy-four percent of evaluable patients held off radiographic progression at six months, clearing the historical 55% benchmark with statistical significance, while a striking 23% remained alive at two years — some after their cancers had already appeared to progress on conventional imaging.
- The regimen's toxicity proved manageable, with no treatment-related deaths, though febrile neutropenia and serious infections occurred in a minority of patients, and RB1 gene loss emerged as a marker of shorter benefit — a clue to the resistance mechanisms still to be overcome.
- Researchers are now calling for randomized controlled trials to determine whether this combination truly extends overall survival and preserves quality of life, or whether the promising signal will soften under the scrutiny of a more rigorous comparison.
This past June in Chicago, Dr. Andrew Armstrong presented results from the CHAMP trial to the American Society of Clinical Oncology — a study aimed at one of prostate cancer's most lethal forms. Neuroendocrine prostate cancer and its aggressive variants move quickly, with median survival historically under a year. Platinum-based chemotherapy offers some control, but only about 55 percent of patients remain progression-free at six months. That has long been the ceiling.
Armstrong's team wondered whether adding immunotherapy could raise it. The CHAMP regimen paired the standard carboplatin-cabazitaxel chemotherapy doublet with two immune checkpoint inhibitors — nivolumab and ipilimumab — in a phase 2 trial enrolling 43 heavily pretreated men. Most had already received hormone therapy and prior chemotherapy. Their tumors bore the molecular fingerprints of resistance: mutations in TP53, RB1, and PTEN, frequent liver and lung metastases, and paradoxically low PSA levels signaling cancers that had evolved beyond hormone dependence.
The results exceeded the trial's own expectations. Seventy-four percent of evaluable patients remained free of radiographic progression at six months — a statistically significant improvement over the historical benchmark. Median progression-free survival by immune-modified criteria reached 12 months. Most remarkably, 23 percent of patients were alive at two years, including some whose cancers had appeared to progress on conventional imaging before stabilizing — a pattern suggesting delayed immune activation. Two patients remained disease-free and off all therapy beyond 30 months.
Toxicity was serious but manageable. Febrile neutropenia occurred in 10 percent of patients, and immune-related complications were rare. No patient died from treatment. One biological signal stood out: tumors with RB1 loss showed shorter benefit, pointing toward a resistance mechanism that future trials may need to address directly.
Armstrong was careful to frame the results as a promising signal rather than a proven advance. Randomized trials are still needed to confirm whether the regimen improves overall survival and quality of life compared to chemotherapy alone. For now, CHAMP offers something this population has rarely had — a credible reason to look further.
In Chicago this June, Dr. Andrew Armstrong stood before the American Society of Clinical Oncology to present results from a trial that might change how doctors treat one of prostate cancer's cruelest variants. The disease he was discussing—neuroendocrine prostate cancer and its aggressive cousins—kills fast. Median survival has historically been measured in months, often less than a year. Standard chemotherapy with platinum compounds helps, but the benefit fades quickly. About 55 percent of patients stay progression-free for six months. That's the baseline. That's what doctors have learned to expect.
Armstrong and his colleagues wondered if they could do better by combining chemotherapy with immunotherapy. They designed the CHAMP trial to test whether adding two immune checkpoint inhibitors—nivolumab and ipilimumab—to the standard platinum-based chemotherapy regimen of carboplatin and cabazitaxel could shift those odds. The logic was sound: emerging data from other cancers suggested this combination might work. The question was whether it would work here, and whether patients could tolerate it.
Forty-three men enrolled across two stages of the study. Most had aggressive-variant disease (70 percent), the rest neuroendocrine prostate cancer. These were heavily pretreated patients—93 percent had already been exposed to hormone-blocking drugs, 78 percent had received prior chemotherapy. Their tumors showed the molecular hallmarks of treatment resistance: frequent mutations in TP53, RB1, and PTEN genes. Many had spread to the liver (58 percent) and lungs (33 percent). Their PSA levels were paradoxically low, a sign their cancers had evolved beyond the hormone-driven growth that PSA typically tracks. Eighty-eight percent had elevated alternative biomarkers like CEA or chromogranin A, the cancer's way of announcing its indifference to standard treatment.
The regimen was intensive: four drugs given together for up to ten cycles, then maintenance therapy with the two immunotherapies alone until the cancer progressed or toxicity became unacceptable. All patients continued their hormone-blocking therapy throughout. The primary question was simple: how many would stay progression-free for six months?
The answer exceeded expectations. Seventy-four percent of evaluable patients—28 of 38—remained free of radiographic progression at six months. That was a statistically significant jump above the 55 percent historical benchmark (p=0.013). When researchers looked further out, the median time to progression by immune-modified criteria reached 12 months. More striking still: despite conventional imaging showing progression in many patients, 23 percent were alive at two years. Some of those alive at two years had neuroendocrine disease (36 percent of that subgroup), others had aggressive-variant cancer (14 percent). Two patients remained disease-free and off all therapy beyond 30 months. Several others showed a pattern oncologists find intriguing—initial progression followed by stabilization or partial response, suggesting the immune system was catching up to the cancer even after conventional measures suggested failure.
The toxicity profile was manageable. Most side effects were mild: anemia, nausea, fatigue, diarrhea, low platelets, low magnesium. Febrile neutropenia—a dangerous drop in infection-fighting white blood cells—occurred in 10 percent. Grade 3 or 4 toxicity happened in 16 and 3 percent respectively. Immune-related complications were rare: one case of severe muscle inflammation, one case of mild pneumonitis. Serious complications like sepsis, urinary tract infections, colitis, and acute kidney injury did occur, but all resolved, and none were fatal. No patient died from treatment itself.
One pattern emerged from the data: patients whose tumors carried RB1 loss—a mutation associated with the cancer's plasticity and treatment resistance—showed shorter periods of benefit. This hints at a biological mechanism of resistance that future trials might target. The tumor mutational burden was low across the cohort (median 3 mutations per megabase), and only one patient had microsatellite instability, suggesting this population would not be expected to respond dramatically to immunotherapy alone. Yet the combination worked.
Armstrong concluded by calling for randomized trials to establish whether this regimen truly improves overall survival and quality of life compared to chemotherapy alone, and to define its long-term toxicity profile. The CHAMP results are promising but preliminary—a signal in a population that has historically had few good options. What comes next is the harder work of proving whether this signal translates into durable benefit for the men who need it most.
Notable Quotes
Chemoimmunotherapy with dual PD-1/CTLA-4 blockade combined with cabazitaxel and carboplatin was feasible and demonstrated acceptable toxicity in patients with neuroendocrine or aggressive-variant prostate cancer.— Dr. Andrew Armstrong, Duke Cancer Institute
Randomized controlled trials are needed to better define the overall risk-benefit profile of chemoimmunotherapy in this population, including its impact on progression, survival, quality of life, and long-term toxicity.— Dr. Andrew Armstrong
The Hearth Conversation Another angle on the story
Why does this trial matter for patients who have already failed hormone therapy?
Because these men are running out of options. Once the cancer stops responding to hormone-blocking drugs, the median survival drops below a year. Chemotherapy helps, but the benefit is brief. This trial shows that adding immunotherapy to chemotherapy can extend that window—doubling the six-month progression-free rate from 55 to 74 percent.
But 74 percent still means one in four patients didn't make it six months. What's happening in those who failed?
That's the hard part. These cancers are biologically aggressive. They've already evolved past hormone sensitivity. Some have mutations in RB1 that seem to predict shorter benefit. We don't yet know if those patients need a different approach entirely, or if timing or dosing matters.
The paper mentions patients who progressed by conventional imaging but were still alive at two years. How does that happen?
Immunotherapy can work slowly. The immune system needs time to recognize and attack the cancer. Some patients showed initial progression, then stabilization or even partial response months later. It's as if the imaging was ahead of the biology—the cancer looked worse before the immune system caught up.
What worries you most about these results?
The lack of a control arm. We don't know if the 12-month median progression-free survival is truly better than chemotherapy alone, or if it's just different. And the toxicity profile, while manageable, includes serious events like sepsis and acute kidney injury. We need randomized data to know if the benefit justifies the risk.
Two patients stayed disease-free off therapy for 30 months. Are they cured?
We don't use that word in metastatic cancer. But yes, they represent something remarkable—durable remission without ongoing treatment. If we could identify who those patients are before treatment starts, we could spare others unnecessary toxicity.
What's the next step?
A randomized trial comparing this combination to chemotherapy alone, with careful attention to overall survival, quality of life, and long-term side effects. These phase 2 results are encouraging enough to justify that investment.